GlycoMimetics

^{Priced, Nasdaq: GLYC}

Clinical-stage biotech developing treatments for sickle cell episodes and AML.

Industry: Health Care

First Day Return: +12.6%

GLYC

Clinical-stage biotech developing treatments for sickle cell episodes and AML.

IPO News for GlycoMimetics

Hypertension biotech Bellerophon Therapeutics sets terms for $60 million IPO 02/03/15
The 'NO' IPO: Nitric oxide biotech Bellerophon Therapeutics files for a $69 million IPO 01/13/15
US IPO Recap: Twenty companies file or set terms for IPOs 01/13/14

IPO Data
IPO Date	01/09/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$56
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.glycomimetics.com
Headquarters	Gaithersburg, MD, United States
Founded	2003
Employees at IPO	28

IPO News for GlycoMimetics

GlycoMimetics (GLYC) Performance